Management of Pregabalin Use Disorder: A Case Series

References

• Bangert, M. K., and G. M. Aisenberg. 2020. Drug deprescription-withdrawal risk, prevention, and treatment. Proceedings (Baylor University. Medical Center) 33 (2):213‑217. doi:10.1080/08998280.2019.1695510.
   PubMedGoogle Scholar
• Barrett, J. A., L. M. Kittler, and C. Singarajah. 2015. Acute pregabalin withdrawal: A case report and review of the literature. Southwest Journal of Pulmonary Critical Care 10 (5):306–10. doi:10.13175/swjpcc059-15.
   Google Scholar
• Bockbrader, H. N., D. Wesche, R. Miller, S. Chapel, N. Janiczek, and P. Burger. 2010. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics 49 (10):661‑669. doi:10.2165/11536200-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Bossard, J. B., C. Ponté, J. Dupouy, M. Lapeyre-Mestre, and E. Jouanjus. 2016. Disproportionality analysis for the assessment of abuse and dependence potential of pregabalin in the French pharmacovigilance database. Clinical Drug Investigation 36 (9):735‑742. doi:10.1007/s40261-016-0421-z.
   PubMed Web of Science ®Google Scholar
• Buttram, M. E., and S. P. Kurtz. 2020. Preliminary evidence of pregabalin misuse among prescription and/or illicit opioid (mis) users. Journal of Psychoactive Drugs 52 (2):172–75. doi:10.1080/02791072.2020.1734695.
   PubMed Web of Science ®Google Scholar
• Cairns, R., A. L. Schaffer, N. Ryan, S. A. Pearson, and N. A. Buckley. 2019. Rising pregabalin use and misuse in Australia: Trends in utilization and intentional poisonings. Addiction 114 (6):1026‑1034. doi:10.1111/add.14412.
   Web of Science ®Google Scholar
• Chiappini, S., and F. Schifano. 2016. A decade of gabapentinoid misuse: An analysis of the European Medicines Agency’s “Suspected adverse drug reactions” database. CNS Drugs 30 (7):647‑654. doi:10.1007/s40263-016-0359-y.
   PubMed Web of Science ®Google Scholar
• Coutens, B., L. Mouledous, M. Stella, C. Rampon, M. Lapeyre-Mestre, A. Roussin, B. P. Guiard, and E. Jouanjus. 2019. Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse. Psychopharmacology 236 (7):2069‑2082. doi:10.1007/s00213-019-05198-z.
   PubMed Web of Science ®Google Scholar
• Driot, D., B. Chicoulaa, E. Jouanjus, J. Dupouy, S. Oustric, and M. Lapeyre-Mestre. 2016. Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapies 71 (6):575‑578. doi:10.1016/j.therap.2016.04.006.
   PubMed Web of Science ®Google Scholar
• Driot, D., E. Jouanjus, S. Oustric, J. Dupouy, and M. Lapeyre-Mestre. 2019. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. British Journal of Clinical Pharmacology 85 (6):1260‑1269. doi:10.1111/bcp.13892.
   PubMed Web of Science ®Google Scholar
• Evoy, K. E., M. D. Morrison, and S. R. Saklad. 2017. Abuse and misuse of pregabalin and gabapentin. Drugs 77 (4):403‑426. doi:10.1007/s40265-017-0700-x.
   Web of Science ®Google Scholar
• Gahr, M., R. W. Freudenmann, C. Hiemke, M. A. Kölle, and C. Schönfeldt-Lecuona. 2013. Pregabalin abuse and dependence in Germany: Results from a database query. European Journal of Clinical Pharmacology 69 (6):1335‑1342. doi:10.1007/s00228-012-1464-6.
   PubMed Web of Science ®Google Scholar
• Gahr, M., R. W. Freudenmann, M. A. Kölle, and C. Schönfeldt-Lecuona. 2015. From benzodiazepine to pregabalin dependence: Different agents, similar problems. Indian Journal of Psychiatry 57 (1): p. 111‑112. doi:10.4103/0019-5545.148551.
   PubMed Web of Science ®Google Scholar
• Grosshans, M., T. Lemenager, C. Vollmert, N. Kaemmerer, R. Schreiner, J. Mutschler, X. Wagner, F. Kiefer, and D. Hermann. 2013. Pregabalin abuse among opiate addicted patients. European Journal of Clinical Pharmacology 69 (12):2021–25. doi:10.1007/s00228-013-1578-5.
   PubMed Web of Science ®Google Scholar
• Grosshans, M., J. Mutschler, D. Hermann, O. Klein, H. Dressing, F. Kiefer, and K. Mann. 2010. Pregabalin abuse, dependence, and withdrawal: A case report. The American Journal of Psychiatry 167 (7):869. doi:10.1176/appi.ajp.2010.09091269.
   PubMed Web of Science ®Google Scholar
• Hellwig, T. R., R. Hammerquist, and J. Termaat. 2010. Withdrawal symptoms after gabapentin discontinuation. American Journal of Health-System Pharmacy 67 (11):910–12. doi:10.2146/ajhp090313.
   PubMed Web of Science ®Google Scholar
• Jouanjus, E., V. Gibaja, J. P. Kahn, F. Haramburu, and A. Daveluy. 2015. Signal identification in addictovigilance: The functioning of the French system. Therapies 70 (2):113–31. doi:10.2515/therapie/2015011.
   PubMed Web of Science ®Google Scholar
• Lancia, M., A. Gambelunghe, A. Gili, M. Bacci, K. Aroni, and K. Gambelunghe. 2019. Pregabalin abuse in combination with other drugs: Monitoring among methadone patients. Frontiers in Psychiatry 10. Accessed February 11, 2020. doi:10.3389/fpsyt.2019.01022.
   PubMed Web of Science ®Google Scholar
• Lapeyre-Mestre, M., A. Boucher, A. Daveluy, V. Gibaja, E. Jouanjus, M. Mallaret, H. Peyrière, and J. Micallef. 2020. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapies 75 (4):343‑354. doi:10.1016/j.therap.2020.06.006.
   Web of Science ®Google Scholar
• Lyndon, A., S. Audrey, C. Wells, E. S. Burnell, S. Ingle, R. Hill, M. Hickman, and G. Henderson. 2017. Risk to heroin users of poly-drug use of pregabalin or gabapentin. Addiction (Abingdon, England) 112 (9):1580‑1589. doi:10.1111/add.13843.
   PubMed Web of Science ®Google Scholar
• McNamara, S., S. Stokes, R. Kilduff, and A. Shine. 2015. Pregabalin abuse amongst opioid substitution treatment patients. Irish Medical Journal 108 (10):309‑310.
   Google Scholar
• Ozturk, M., and G. Morkavuk. 2019. Nasal pregabalin overdose and myoclonus: A new way of misuse. Psychiatry and Clinical Psychopharmacology 29 (2):216‑219. doi:10.1080/24750573.2017.1422959.
   Web of Science ®Google Scholar
• Parsons, G. 2018. Guide to the management of gabapentinoid misuse. Prescriber 29 (4):25–30. doi:10.1002/psb.1664.
   Google Scholar
• Schifano, F. 2014. Misuse and abuse of pregabalin and gabapentin: Cause for concern? CNS Drugs 28 (6):491‑496. doi:10.1007/s40263-014-0164-4.
   PubMed Web of Science ®Google Scholar
• Schjerning, O., M. Rosenzweig, A. Pottegård, P. Damkier, and J. Nielsen. 2016. Abuse potential of pregabalin: A systematic review. CNS Drugs 30 (1):9‑25. doi:10.1007/s40263-015-0303-6.
   PubMed Web of Science ®Google Scholar
• Schwan, S., A. Sundström, E. Stjernberg, E. Hallberg, and P. Hallberg. 2010. A signal for an abuse liability for pregabalin – Results from the Swedish spontaneous adverse drug reaction reporting system. European Journal of Clinical Pharmacology 66 (9):947‑953. doi:10.1007/s00228-010-0853-y.
   PubMed Web of Science ®Google Scholar
• Snellgrove, B. J., T. Steinert, and S. Jaeger. 2017. Pregabalin use among users of illicit drugs: A cross-sectional survey in Southern Germany. CNS Drugs 31 (10):891–98. doi:10.1007/s40263-017-0467-3.
   PubMed Web of Science ®Google Scholar
• Toce, M. S., P. R. Chai, M. M. Burns, and E. W. Boyer. 2018. Pharmacologic treatment of opioid use disorder: A review of pharmacotherapy, adjuncts, and toxicity. Journal of Medical Toxicology 14 (4):302–22. doi:10.1007/s13181-018-0685-1.
   Web of Science ®Google Scholar
• Tremont-Lukats, I., C. Megeff, and M. M. Backonja. 2000. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 60 (5):1029‑1052. doi:10.2165/00003495-200060050-00005.
   PubMed Web of Science ®Google Scholar
• World Health Organization – Expert Committee on Drug Dependence. 2018. Critical review report: Pregabalin. 41, Geneva.
   Google Scholar